Dashboard
Manage Tickers

BNTXBioNTech SE

Nasdaq biontech.de


$ 79.21 $ -0.25 (-0.31 %)    

Wednesday, 07-Aug-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.72 $ -4.76 (-1.08 %)
DIA $ 387.79 $ -2.19 (-0.56 %)
SPY $ 518.50 $ -3.49 (-0.67 %)
TLT $ 95.87 $ -0.68 (-0.7 %)
GLD $ 220.55 $ -0.15 (-0.07 %)
$ 79.25
$ 81.39
$ 76.11 x 187
-- x --
$ 78.51 - $ 81.59
$ 76.53 - $ 125.83
783,215
na
18.84M
$ 0.07
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-cognizant-technology-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-wednesday
This Cognizant Technology Analyst Is No Lo...
08/07/2024 12:46:06

deutsche-bank-upgrades-biontech-to-buy-maintains-price-target-to-95
Deutsche Bank Upgrades BioNTech to Buy, Ma...
08/07/2024 09:16:35

Deutsche Bank analyst Emmanuel Papadakis upgrades BioNTech (NASDAQ:BNTX) from Hold to Buy and maintains the price target fro...

Core News & Articles
University Of Pennsylvania Sues BioNTech F...
08/06/2024 18:52:40

- Reuters 

td-cowen-maintains-hold-on-biontech-lowers-price-target-to-85
TD Cowen Maintains Hold on BioNTech, Lower...
08/06/2024 16:48:53

TD Cowen analyst Yaron Werber maintains BioNTech (NASDAQ:BNTX) with a Hold and lowers the price target from $98 to $85.

us-stocks-trim-black-mondays-drops-as-services-gauge-expands-bond-gains-stall-as-traders-reassess-fed-cuts-whats-driving-markets
US Stocks Trim Black Monday's Drops As Ser...
08/05/2024 17:11:24

Global markets are experiencing intense volatility, and while it seemed like a Black Monday for Wall Street was inevitable foll...

biontechs-q2-loss-widens-amid-low-demand-for-its-pfizer-partnered-covid-19-vaccine-increases-rd-spending-on-new-cancer-products
BioNTech's Q2 Loss Widens Amid Low Demand ...
08/05/2024 11:59:26

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID...

nasdaq-r2k-futures-tumble-over-4-vix-spikes-over-100-bitcoin-plunges-hard-as-global-sell-off-deepens-amid-recession-fears
Nasdaq, R2K Futures Tumble Over 4%, VIX Sp...
08/05/2024 11:51:10

The stock market is on track to gap-open sharply lower on Monday as negative sentiment seen in the final two sessions of last w...

biontech-reiterates-2024-revenues-guidance-of-25b-31b-ended-the-second-quarter-of-2024-with-185b-in-cash-cash-equivalents-and-security-investments
BioNTech Reiterates 2024 Revenues Guidance...
08/05/2024 10:03:32

biontech-q2-2024-gaap-eps-eur336-misses-eur189-estimate-sales-eur128700m-miss-eur157008m-estimate
BioNTech Q2 2024 GAAP EPS EUR(3.36) Misses...
08/05/2024 10:01:55

Core News & Articles
Genmab Takes Over Acasunlimab Development,...
08/05/2024 09:53:21

 Genmab A/S (NASDAQ: GMAB) announced today that it will assume sole responsibility for the continued development and potential ...

navigating-12-analyst-ratings-for-biontech
Navigating 12 Analyst Ratings For BioNTech
08/01/2024 12:00:44

hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target
HC Wainwright & Co. Reiterates Buy on BioN...
08/01/2024 10:20:52

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

biontech-reports-topline-data-from-ongoing-phase-2-clinical-trial-for-mrna-immunotherapy-candidate-bnt111-for-advanced-melanoma-trial-met-its-primary-efficacy-outcome-measure
BioNTech Reports Topline Data From Ongoing...
07/30/2024 10:47:04

The Phase 2 trial will continue as planned to further assess the secondary endpoints, which were not mature at the time of the ...

european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-on-ursula-von-der-leyens-reappointment
European Commission Faces Court Criticism ...
07/17/2024 18:24:05

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implication...

Core News & Articles
CureVac Announced The Latest Trial Dates F...
07/11/2024 11:20:10

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...

gsk-buys-full-rights-to-investigational-covid-19-and-influenza-vaccines-from-curevac-for-around-15b
GSK Buys Full Rights To Investigational Co...
07/03/2024 12:01:25

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...

london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents
London High Court Ruling Fuels Pfizer And ...
07/02/2024 16:59:34

Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Cour...

abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway
AbbVie/Genmab's Epkinly FDA Approval Is A ...
06/27/2024 17:22:09

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...

Core News & Articles
Pfizer And BioNTech Receive Positive CHMP ...
06/27/2024 14:31:17

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months ...

evaluating-biontech-insights-from-12-financial-analysts
Evaluating BioNTech: Insights From 12 Fina...
06/26/2024 12:00:26

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION